153 related articles for article (PubMed ID: 22223700)
1. Which metastasis management allows long-term survival of synchronous solitary M1b non-small cell lung cancer?
Mordant P; Arame A; De Dominicis F; Pricopi C; Foucault C; Dujon A; Le Pimpec-Barthes F; Riquet M
Eur J Cardiothorac Surg; 2012 Mar; 41(3):617-22. PubMed ID: 22223700
[TBL] [Abstract][Full Text] [Related]
2. Perioperative and oncologic outcomes of pulmonary resection for synchronous oligometastatic non-small cell lung cancer: Evidence for surgery in advanced disease.
Deboever N; Mitchell KG; Farooqi A; Ludmir EB; Hofstetter WL; Mehran RJ; Rajaram R; Rice DC; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Heymach JV; Gomez DR; Gandhi SJ; Antonoff MB
J Thorac Cardiovasc Surg; 2024 Jun; 167(6):1929-1935.e2. PubMed ID: 37619884
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Impact of Visceral Pleural Invasion in Resected Solitary Lung Metastases from Gastric Cancer.
Shigenobu T; Ohtsuka T; Hanawa R; Sakamaki H; Yoshizu A; Tajima A
Ann Thorac Cardiovasc Surg; 2023 Dec; 29(6):279-286. PubMed ID: 37316253
[TBL] [Abstract][Full Text] [Related]
4. The Nine-Year Survival of Patients Operated for Non-Small-Cell Lung Carcinoma in a Tertiary Centre: The Impact of the Tumour Stage and Other Patient-Related Parameters.
Vlăsceanu S; Mahler B; Marghescu AȘ; Bădărău IA; Moldovan H; Gheorghiță D; Costache M; Savu C
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541141
[No Abstract] [Full Text] [Related]
5. Complete resection of the primary lesion improves survival of certain patients with stage IV non-small cell lung cancer.
Chikaishi Y; Shinohara S; Kuwata T; Takenaka M; Oka S; Hirai A; Yoneda K; Kuroda K; Imanishi N; Ichiki Y; Tanaka F
J Thorac Dis; 2017 Dec; 9(12):5278-5287. PubMed ID: 29312736
[TBL] [Abstract][Full Text] [Related]
6. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.
Ashworth AB; Senan S; Palma DA; Riquet M; Ahn YC; Ricardi U; Congedo MT; Gomez DR; Wright GM; Melloni G; Milano MT; Sole CV; De Pas TM; Carter DL; Warner AJ; Rodrigues GB
Clin Lung Cancer; 2014 Sep; 15(5):346-55. PubMed ID: 24894943
[TBL] [Abstract][Full Text] [Related]
7. Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450).
De Ruysscher D; Wanders R; Hendriks LE; van Baardwijk A; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Dingemans AC
J Thorac Oncol; 2018 Dec; 13(12):1958-1961. PubMed ID: 30253974
[TBL] [Abstract][Full Text] [Related]
8. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer.
Eberhardt WE; Mitchell A; Crowley J; Kondo H; Kim YT; Turrisi A; Goldstraw P; Rami-Porta R;
J Thorac Oncol; 2015 Nov; 10(11):1515-22. PubMed ID: 26536193
[TBL] [Abstract][Full Text] [Related]
9. Oligometastases.
Hellman S; Weichselbaum RR
J Clin Oncol; 1995 Jan; 13(1):8-10. PubMed ID: 7799047
[No Abstract] [Full Text] [Related]
10. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
[TBL] [Abstract][Full Text] [Related]
11. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?
Vecht CJ; Haaxma-Reiche H; Noordijk EM; Padberg GW; Voormolen JH; Hoekstra FH; Tans JT; Lambooij N; Metsaars JA; Wattendorff AR
Ann Neurol; 1993 Jun; 33(6):583-90. PubMed ID: 8498838
[TBL] [Abstract][Full Text] [Related]
12. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Zhou C; Wang Z; Sun Y; Cao L; Ma Z; Wu R; Yu Y; Yao W; Chang J; Chen J; Zhuang W; Cui J; Chen X; Lu Y; Shen H; Wang J; Li P; Qin M; Lu D; Yang J
Lancet Oncol; 2022 Feb; 23(2):220-233. PubMed ID: 35038432
[TBL] [Abstract][Full Text] [Related]
13. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.
Ren S; Chen J; Xu X; Jiang T; Cheng Y; Chen G; Pan Y; Fang Y; Wang Q; Huang Y; Yao W; Wang R; Li X; Zhang W; Zhang Y; Hu S; Guo R; Shi J; Wang Z; Cao P; Wang D; Fang J; Luo H; Geng Y; Xing C; Lv D; Zhang Y; Yu J; Cang S; Yang Z; Shi W; Zou J; Zhou C;
J Thorac Oncol; 2022 Apr; 17(4):544-557. PubMed ID: 34923163
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.
Lu S; Wang Q; Zhang G; Dong X; Yang CT; Song Y; Chang GC; Lu Y; Pan H; Chiu CH; Wang Z; Feng J; Zhou J; Xu X; Guo R; Chen J; Yang H; Chen Y; Yu Z; Shiah HS; Wang CC; Yang N; Fang J; Wang P; Wang K; Hu Y; He J; Wang Z; Shi J; Chen S; Wu Q; Sun C; Li C; Wei H; Cheng Y; Su WC; Hsia TC; Cui J; Sun Y; Ou SI; Zhu VW; Chih-Hsin Yang J
J Thorac Oncol; 2022 Mar; 17(3):411-422. PubMed ID: 34801749
[TBL] [Abstract][Full Text] [Related]
15. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12).
Zhou C; Wu L; Fan Y; Wang Z; Liu L; Chen G; Zhang L; Huang D; Cang S; Yang Z; Zhou J; Zhou C; Li B; Li J; Fan M; Cui J; Li Y; Zhao H; Fang J; Xue J; Hu C; Sun P; Du Y; Zhou H; Wang S; Zhang W
J Thorac Oncol; 2021 Sep; 16(9):1501-1511. PubMed ID: 34048947
[TBL] [Abstract][Full Text] [Related]
16. Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial.
Lu S; Wang J; Yu Y; Yu X; Hu Y; Ai X; Ma Z; Li X; Zhuang W; Liu Y; Li W; Cui J; Wang D; Liao W; Zhou J; Wang Z; Sun Y; Qiu X; Gao J; Bao Y; Liang L; Wang M
J Thorac Oncol; 2021 Sep; 16(9):1512-1522. PubMed ID: 34033975
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
Nishio M; Barlesi F; West H; Ball S; Bordoni R; Cobo M; Longeras PD; Goldschmidt J; Novello S; Orlandi F; Sanborn RE; Szalai Z; Ursol G; Mendus D; Wang L; Wen X; McCleland M; Hoang T; Phan S; Socinski MA
J Thorac Oncol; 2021 Apr; 16(4):653-664. PubMed ID: 33333328
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Wei YC; Liu YY; Chen C; Cheng Y; Yin R; Yang F; Ren SX; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yang JJ; Yan HH; Yang XN; Liu SY; Zhou Q; Wu YL
J Clin Oncol; 2021 Mar; 39(7):713-722. PubMed ID: 33332190
[TBL] [Abstract][Full Text] [Related]
20. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
Travis WD; Dacic S; Wistuba I; Sholl L; Adusumilli P; Bubendorf L; Bunn P; Cascone T; Chaft J; Chen G; Chou TY; Cooper W; Erasmus JJ; Ferreira CG; Goo JM; Heymach J; Hirsch FR; Horinouchi H; Kerr K; Kris M; Jain D; Kim YT; Lopez-Rios F; Lu S; Mitsudomi T; Moreira A; Motoi N; Nicholson AG; Oliveira R; Papotti M; Pastorino U; Paz-Ares L; Pelosi G; Poleri C; Provencio M; Roden AC; Scagliotti G; Swisher SG; Thunnissen E; Tsao MS; Vansteenkiste J; Weder W; Yatabe Y
J Thorac Oncol; 2020 May; 15(5):709-740. PubMed ID: 32004713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
